Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | September 19, 2026 | September 22, 2026 |
| Moelis & CoMC · Entity 3898 | Director | November 14, 2018 | November 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 08, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,802 |
Reported balance
After 2026-09-19 transaction · row 1
1 source rowRow 1 · 2026-09-19 · Grant · Acquired 107 · Balance 95,802 F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 407 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 407 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Moelis & Co
Report date November 14, 2018 · Filed November 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2017 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,156.96 |
Reported balance
After 2018-11-14 transaction · row 1
1 source rowRow 1 · 2018-11-14 · Grant · Acquired 13.39 · Balance 1,156.96 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 706.23 |
Reported balance
After 2018-11-14 transaction · row 2
1 source rowRow 2 · 2018-11-14 · Grant · Acquired 8.17 · Balance 706.23 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Elective Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,059.34 |
Reported balance
After 2018-11-14 transaction · row 3
1 source rowRow 3 · 2018-11-14 · Grant · Acquired 12.26 · Balance 1,059.34 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock.
F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
Pacira BioSciences, Inc.
Report date June 08, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,247 |
Reported balance
After 2022-06-08 transaction · row 1
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 1,160 · Balance 13,247 F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.39 · Expires 2032-06-08 | Direct | 8,225 |
Reported balance
After 2022-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-08 · Grant · Acquired 8,225 · Balance 8,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 847 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · derivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 847 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 26, 2024. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,352 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · derivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,352 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 28, 2023. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1,121 | $445.12 | $498,979.52 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,985 Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 659 | $151.59 | $99,897.81 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 847 | $118.05 | $99,988.35 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,352 | $85.00 | $199,920.00 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 839 | $119.13 | $99,950.07 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2017 (right to buy) · Derivative | 10,000 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · derivative · entry 27 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F22 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 11, 2021. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 261 | $456.03 | $119,023.83 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 23 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,409 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 195 | $454.69 | $88,664.55 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 22 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,670 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 881 | $453.99 | $399,965.19 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 21 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,865 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F19 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.55 to $454.46. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,599 | $452.85 | $724,107.15 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 20 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,746 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F18 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.51 to $453.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,702 | $451.94 | $769,201.88 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 19 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,345 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.60 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,218 | $450.69 | $999,630.42 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 18 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,047 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.56 to $451.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,477 | $450.02 | $664,679.54 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 17 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,265 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.50 to $450.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,013 | $448.76 | $454,593.88 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 16 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,742 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.38 to $449.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 654 | $447.73 | $292,815.42 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 15 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,755 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.30 to $448.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $119.13 | $1,191,300.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 14 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2017 (right to buy) · Derivative | 15,000 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · derivative · entry 26 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F22 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 11, 2021. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 650 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · derivative · entry 25 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F21 · derivative.exercise_date: This stock option was fully vested and exercisable as of August 6, 2019. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 430 | $458.42 | $197,120.60 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,409 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $458.37 to $458.56. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 604 | $457.71 | $276,456.84 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,839 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.24 to $458.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,420 | $456.64 | $1,105,068.80 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,443 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $456.22 to $457.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,406 | $455.56 | $1,551,637.36 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,863 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.17 to $456.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,960 | $454.84 | $891,486.40 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,269 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.16 to $455.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,069 | $453.52 | $484,812.88 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,229 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.14 to $454.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,210 | $452.43 | $547,440.30 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,298 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.95 to $452.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,255 | $451.16 | $566,205.80 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,508 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.75 to $451.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 453 | $450.17 | $203,927.01 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,763 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.72 to $450.64. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,132 | $449.15 | $957,587.80 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,216 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.69 to $449.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 711 | $448.07 | $318,577.77 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,348 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.67 to $448.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $119.13 | $1,786,950.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 650 | $42.22 | $27,443.00 |
DisclosureSEC source: 0001735276-25-000120 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 13, 2025. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 9 | $457.64 | $4,118.76 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 14 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,409 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 446 | $457.43 | $204,013.78 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,418 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 221 | $455.82 | $100,736.22 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,864 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 741 | $454.84 | $337,036.44 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,085 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 999 | $453.77 | $453,316.23 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,826 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,029 | $452.69 | $918,508.01 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,825 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,010 | $451.86 | $456,378.60 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,854 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,642 | $450.81 | $740,230.02 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,864 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 758 | $449.79 | $340,940.82 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,506 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 548 | $448.77 | $245,925.96 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,264 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 171 | $447.92 | $76,594.32 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,812 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 350 | $446.53 | $156,285.50 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,983 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 14,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,333 F2 · kind: On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000116 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,081 F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 60 | $455.82 | $27,349.20 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,221 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,204 | $454.84 | $547,627.36 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,281 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,716 | $454.04 | $1,233,172.64 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,485 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.